![](https://medcitynews.com/wp-content/uploads/sites/7/2016/12/GettyImages-185085872.jpg)
Safety concerns sink Akebia drug for anemia from chronic kidney disease
The FDA rejected Akebia Therapeutics drug vadadustat as a treatment for anemia caused by chronic kidney disease. According to the biotech, the agency cited safety concerns and asked for another clinical trial to show that the pill’s benefits outweigh its risks.